Latest News

The FDA recently approved the first generic baloxavir tablet for influenza treatment and postexposure prophylaxis in patients aged 5 years or older.

CGM prescribing in primary care was associated with lower HbA1c levels, fewer hospitalizations, and fewer ED visits among insulin-treated adults.

A primary care telehealth mindfulness program improved chronic low back pain and pain interference through 12 months in OPTIMUM.

FDA authorized a reduced-risk claim for 20 ZYN nicotine pouches for adults who switch completely from cigarettes.

A 10-week video-based cognitive rehabilitation program improved patient-set goals in adults with long COVID cognitive symptoms.

Recent FDA actions include updates on COVID-19 prophylaxis, ADHD, PTSD neuromodulation, and pediatric psoriasis and psoriatic arthritis care.

FDA approved roflumilast (Zoryve) cream 0.3% for plaque psoriasis in children as young as age 2, expanding the once-daily steroid-free topical indication.

A deep learning ECG model identified a high-risk group with a 7.0% annual sudden cardiac death rate in a new study.